Serentis closes L10M financing
Serentis, a privately owned biopharmaceutical company based in Cambaridge, UK, has closed a L10.0 million ($19.2 million) financing, expanding the total of its series A funding to L15.3 million. The proceeds will be used to advance and expand Serentis' dermatology pipeline.
In July 2007, Serentis announced a L10.3 million series A financing co-led by founding investors MVM Life Science Partners, Apposite Capital and Denmark's Novo A/S. The planned second tranche of L5.0 million has been expanded to L10.0 million, supported by the same co-lead investors and new investor Healthcare Private Equity, the Scottish Widows health care venture fund. East Hill, the Boston-based venture capital firm which became a shareholder in Serentis following the acquisition of Surface Therapeutics in September 2007, also participated in the round.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze